{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:12:26Z","timestamp":1782864746159,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"31","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>As the outcome of immunotherapy can be improved when concurrently or sequentially combined with cytotoxic chemotherapy or radiotherapy, we investigated the efficacy of immunotherapy maintenance following platinum\u2010based chemotherapy in epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>)\u2010mutant non\u2010small cell lung cancer (NSCLC) after EGFR\u2010tyrosine kinase inhibitor (EGFR\u2010TKI) failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective, open\u2010label, single arm phase 2 trial, we enrolled patients aged 18\u2009years or older with <jats:italic>EGFR<\/jats:italic>\u2010mutant NSCLC, which progressed after first\u2010 or second\u2010line EGFR\u2010TKI. Patients received platinum\u2010based chemotherapy followed by nivolumab maintenance therapy. They were intravenously administered 240\u2009mg of nivolumab every 2\u2009weeks for 3\u2009months followed by 480\u2009mg every 4\u2009weeks until disease progression or unacceptable toxic effects occurred. The primary endpoint was progression\u2010free survival (PFS). Secondary outcomes were overall survival (OS) and incidence of grade 3\u20134 treatment\u2010related adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We enrolled 26 patients between May 2020 and July 2021. The median PFS was 1.7\u2009months (95% CI: 0.401\u20132.999\u2009months). The median OS was 21.4\u2009months (95% CI: 18.790\u201324.010\u2009months) with 6\u2010 and 12\u2010month OS rates of 96.2% and 76.9%, respectively. The objective response rate was 7.7% (2\/26) and disease control rate, 11.5% (3\/26). The tumor mutational burden by next\u2010generation sequencing in blood was not related to the treatment outcomes. Grade 3\u20134 treatment\u2010related AEs occurred in four (15.4%) patients; the most frequent AE was increased alanine aminotransferase (7.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Nivolumab maintenance following platinum\u2010based chemotherapy did not show clinical benefits after EGFR\u2010TKI failure in patients with <jats:italic>EGFR<\/jats:italic>\u2010mutant NSCLC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.15083","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T01:50:34Z","timestamp":1694569834000},"page":"3080-3088","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab as maintenance therapy following platinum\u2010based chemotherapy in <scp><i>EGFR<\/i><\/scp>\u2010mutant lung cancer patients after tyrosine kinase inhibitor failure: A single\u2010arm, open\u2010label, phase 2 trial"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-210X","authenticated-orcid":false,"given":"Jiwon","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Asan Medical Center University of Ulsan College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2881-4669","authenticated-orcid":false,"given":"Chang\u2010Min","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Asan Medical Center University of Ulsan College of Medicine  Seoul South Korea"},{"name":"Department of Oncology, Asan Medical Center University of Ulsan College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7164-2770","authenticated-orcid":false,"given":"Wonjun","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Asan Medical Center University of Ulsan College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-0259","authenticated-orcid":false,"given":"Jae Cheol","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Asan Medical Center University of Ulsan College of Medicine  Seoul South Korea"},{"name":"Department of Oncology, Asan Medical Center University of Ulsan College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.128"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183"},{"issue":"5","key":"e_1_2_8_5_1","article-title":"First\u2010line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non\u2010squamous non\u2010small cell lung cancer","author":"Greenhalgh J","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044238"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020073"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm564"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24657"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.05.023"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9861"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw416"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12851"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.007"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427"},{"issue":"11","key":"e_1_2_8_20_1","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD\u20101 blockade in non\u2010small cell lung cancer","volume":"6","author":"Dong ZY","year":"2017","journal-title":"Onco Targets Ther"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0310"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.555"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1102"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.63"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv054"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy495"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3384"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01042"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"issue":"17","key":"e_1_2_8_36_1","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)\u2010resistant, EGFR\u2010mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE\u2010789 study","volume":"41","author":"Lee DH","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T07:56:25Z","timestamp":1699257385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":35,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/1759-7714.15083"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15083","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"2023-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}